Description
PHARMACEUTICAL: TYMLOS (ABALOPARATIDE)
First action · last action
2024-02-28 · 2025-05-12
Transactions
7
First transaction's obligation
$2,105,561
Base + all options value (sum of deltas)
$16,443,427
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
3
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 7 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2024-02-28+$2,105,561= $2,105,561
- Mod P000012024-05-21+$4,152,634= $6,258,195
- Mod P000022024-08-22+$3,835,129= $10,093,323
- Mod P000032024-10-16+$3,835,129= $13,928,452
- Mod P000042025-03-06+$2,916,035= $16,844,486
- Mod P000052025-03-26+$0= $16,844,486
- Mod P000062025-05-12-$401,059= $16,443,427
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2024-02-28 | +$2,105,561 | $2,105,561 | PHARMACEUTICAL: TYMLOS (ABALOPARATIDE) |
| Mod P00001· EXERCISE AN OPTION | 2024-05-21 | +$4,152,634 | $6,258,195 | PHARMACEUTICAL: TYMLOS (ABALOPARATIDE) |
| Mod P00002· EXERCISE AN OPTION | 2024-08-22 | +$3,835,129 | $10,093,323 | PHARMACEUTICAL: TYMLOS (ABALOPARATIDE) |
| Mod P00003· EXERCISE AN OPTION | 2024-10-16 | +$3,835,129 | $13,928,452 | PHARMACEUTICAL: TYMLOS (ABALOPARATIDE) |
| Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-03-06 | +$2,916,035 | $16,844,486 | PHARMACEUTICAL: TYMLOS (ABALOPARATIDE) |
| Mod P00005· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-03-26 | +$0 | $16,844,486 | PHARMACEUTICAL: TYMLOS (ABALOPARATIDE) |
| Mod P00006· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-05-12 | −$401,059 | $16,443,427 | PHARMACEUTICAL: TYMLOS (ABALOPARATIDE) |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI EMHFNF3LKVM6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26123P1050 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $17,559 | FY2023 |
| 36C26123P0438 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $16,228 | FY2023 |
| 36C26123P0189 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $16,228 | FY2023 |
| 36C26122P1611 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $16,228 | FY2022 |
| 36C26122P0229 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $15,398 | FY2022 |
| 36C26121P1663 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $15,398 | FY2021 |
Other recipients under 6505 from NATIONAL CMOP OFFICE (36C770) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C77026P0118 | HYGEN PHARMACEUTICALS INC | NATIONAL CMOP OFFICE (36C770) | $30,935 | FY2026 |
| 36C77026P0129 | DERRAH MORRISON ENTERPRISES LLC | NATIONAL CMOP OFFICE (36C770) | $76,656 | FY2026 |
| 36C77026P0127 | DERRAH MORRISON ENTERPRISES LLC | NATIONAL CMOP OFFICE (36C770) | $58,395 | FY2026 |
| 36C77026P0086 | SAGENT PHARMACEUTICALS, INC | NATIONAL CMOP OFFICE (36C770) | $275,580 | FY2026 |
| 36C77026P0095 | HYGEN PHARMACEUTICALS INC | NATIONAL CMOP OFFICE (36C770) | $83,520 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C77024C0001_3600_-NONE-_-NONE- · retrieved 2026-09-26.